Acadia Pharmaceuticals Wins Patent Case for NUPLAZID

ACADIA Pharmaceuticals ( (ACAD) ) has issued an update.

On June 9, 2025, Acadia Pharmaceuticals announced that the U.S. Court of Appeals for the Federal Circuit upheld a previous decision by the U.S. District Court for the District of Delaware, confirming the validity of the company’s composition of matter patent for NUPLAZID® (pimavanserin). This legal victory against MSN Laboratories and its affiliate MSN Pharmaceuticals reinforces Acadia’s patent position, potentially strengthening its market position and providing assurance to stakeholders regarding the protection of its intellectual property.

The most recent analyst rating on (ACAD) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.

Spark’s Take on ACAD Stock

According to Spark, TipRanks’ AI Analyst, ACAD is a Outperform.

ACADIA Pharmaceuticals’ strong financial performance and positive earnings call are key strengths, driving a favorable overall score. Technical indicators show bullish momentum, though caution is advised due to overbought conditions. The company’s valuation is reasonable, and recent corporate events further bolster its strategic position.

To see Spark’s full report on ACAD stock, click here.

More about ACADIA Pharmaceuticals

Acadia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative medicines to address unmet medical needs in central nervous system disorders. Its primary product is NUPLAZID® (pimavanserin), which is used for the treatment of Parkinson’s disease psychosis.

Average Trading Volume: 2,067,941

Technical Sentiment Signal: Buy

Current Market Cap: $3.68B

Learn more about ACAD stock on TipRanks’ Stock Analysis page.